- Home
- SBFG vs ABOS Comparison
SBFG vs ABOS Comparison
Compare SBFG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | ABOS |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 114.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBFG | ABOS |
|---|---|---|
| Price | $22.06 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 9.8K | ★ 1.2M |
| Earning Date | 01-29-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.79% | N/A |
| EPS Growth | ★ 27.54 | N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $64,543,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.15 | ★ N/A |
| Revenue Growth | ★ 13.68 | N/A |
| 52 Week Low | $17.10 | $0.86 |
| 52 Week High | $24.48 | $3.05 |
Technical Indicators
Market Signals| Indicator | SBFG | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 58.67 |
| Support Level | $21.66 | $1.76 |
| Resistance Level | $22.99 | $3.05 |
| Average True Range (ATR) | 0.83 | 0.30 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 58.09 | 53.79 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.